

Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

<https://marketpublishers.com/r/S35EFA975E18EN.html>

Date: September 2019

Pages: 127

Price: US\$ 2,750.00 (Single User License)

ID: S35EFA975E18EN

Abstracts

REPORT SCOPE:

The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.

REPORT INCLUDES:

Information on the top potential drug launches by pharma companies in 2019

Knowledge about drug, mechanism of action, and briefing of clinical evidences

Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more

Insights into regulatory approvals, market scope, and analysis of pipeline molecules

Detailed profiles of the companies and competitors related to the industry

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SIGNIFICANT DRUG LAUNCHES

CHAPTER 3 ULTOMIRIS (RAVULIZUMAB)

Overview of Ultomiris
Scientific Summary
Pharmacodynamics and Mechanism of Action
Pharmacokinetics
Therapeutic Trials of Ultomiris on Safety and Efficacy
Adverse Drug Reactions
Disease Background
Epidemiology of PNH
Pathophysiology
Symptoms of PNH
Currently Available Treatment for PNH
Pipeline Molecules for PNH
Regulatory and Development Milestones of Ultomiris
Market Scope for Ultomiris
Current PNH Market
Ultomiris Market
Market Drivers
Pharmaceutical Pricing and Reimbursement
Ultomiris Exclusivity
Company Profile
ALEXION PHARMACEUTICALS INC.

CHAPTER 4 RINVOQ (UPADACITINIB)

Drug Overview
Scientific Summary
Pharmacodynamics and Mechanism of Action
Pharmacokinetics
Therapeutic Trials of Upadacitinib on Safety and Efficacy
Adverse Drug Reactions
Disease Background
Epidemiology
Pathophysiology of RA
Etiology
Symptoms of RA
Unmet Needs
Current Available Treatment for RA
Pipeline Molecules
Regulatory Status of Upadacitinib
Market Scope for Upadacitinib
Current RA Market
Market Drivers
Upadacitinib Market
Company Profile
ABBVIE INC.

CHAPTER 5 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Disease Background
Classification of SMA
Epidemiology
Pathophysiology
SMA Therapeutics Pipeline
Currently Available Treatment for SMA
Market Scope for Drug XX
Current SMA Market
Drivers for SMA Market
Drug XX Market

Company Profile
NOVARTIS AG

CHAPTER 6 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials of Brolucizumab on Safety and Efficacy
Disease Background
Epidemiology
Disease Subtypes
Classification of AMD
Etiology
Pathophysiology
Unmet Needs of AMD
Currently Available Treatment for AMD
Laser Photocoagulation
Photodynamic Therapy
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs
Pipeline Molecules for AMD
Status of Regulatory Approval of Drug XX
Market Scope for Drug XX
Current Market Size of AMD
Market Drivers
Impact of Drug XX on AMD Market
Company Profile

CHAPTER 7 DRUG XX

Drug Overview
Scientific Summary
Pharmacokinetics
Mechanism of Action
Adverse Events
Therapeutic Trials on Safety and Efficacy of Mayzent
Disease Background
Epidemiology
Pathophysiology

Types of MS
Symptoms of MS
Unmet Needs of MS
Regulatory Approval of Drug XX
Current Available Treatment for MS
Pipeline Molecules for MS
Market Scope for Drug XX
Current Multiple Sclerosis Market
Impact of Drug XX on MS Market
Company Profiles

CHAPTER 8 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Pharmacokinetics
Therapeutic Trials on Efficacy and Safety of Risankizumab
Disease Background
Epidemiology
Pathophysiology
Types of Psoriasis
Regulatory and Development Milestones
Currently Available Treatment for Psoriasis
Biologics
Systemics
Phototherapy
Pipeline Molecules
Market Scope for Drug XX
Current Psoriasis Market
Drug XX Market
Company Profiles

CHAPTER 9 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Safety and Efficacy of LentiGlobin

Disease Background
Epidemiology
Types of Thalassemia
Pathophysiology
Regulatory and Development Milestones
Currently Available Treatment
Chelating Therapy
Pipeline Molecules
Market Scope for Drug XX
Current Beta Thalassemia Market
Drug XX Market
Company Profile
BLUEBIRD BIO INC.

CHAPTER 10 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Safety and Efficacy of Ozanimod
Disease Background
Epidemiology
Pathophysiology
Types of MS
Symptoms of MS
Unmet Needs of MS
Currently Available Treatment for MS
Pipeline Molecules of MS
Regulatory and Developmental Milestones
Market Scope for Drug XX
Company Profile
CELGENE CORP.

CHAPTER 11 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Safety and Efficacy of AR101

Disease Background
Types of Allergic Reactions
Focus on Peanut Allergy
Management of Peanut Allergy
Regulatory and Development Milestones
Market Scope for Drug XX
Company Profile
AIMMUNE THERAPEUTICS INC.

CHAPTER 12 DRUG XX

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Efficacy and Safety of Filgotinib
Disease Background
Epidemiology
Pathophysiology of RA
Etiology
Symptoms of RA
Unmet Needs
Currently Available Treatment for Rheumatoid Arthritis
Pipeline Molecules
Market Scope for Drug XX
Current RA Market
Drug XX Market
Company Profile
GILEAD SCIENCES INC.

CHAPTER 13 CONCLUSION

CHAPTER 14 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

- Table 1: Potential Launches to Watch, 2019
- Table 2: Top Companies Investing in R&D, 2018
- Table 3: Potential Drug Launches, 2018
- Table 4: Key Clinical Trials of Ultomiris
- Table 5: Common Symptoms of PNH
- Table 6: Other Pipeline Drugs for PNH
- Table 7: Key Development Milestones of Ultomiris
- Table 8: Alexion Pharmaceuticals Inc.: Financial Performance, 2016-2018
- Table 9: Alexion Pharmaceuticals Inc.: Product Portfolio
- Table 10: Alexion Pharmaceuticals Inc.: Pipeline Molecules
- Table 11: Alexion Pharmaceuticals, Inc.: Recent Acquisitions
- Table 12: Clinical Evidence of Safety and Efficacy of Upadacitinib
- Table 13: Epidemiological Forecast for Diagnosed Prevalent Cases of Rheumatoid Arthritis, by Region, Through 2022
- Table 14: Common Symptoms of RA
- Table 15: Unmet Needs of RA
- Table 16: Current Treatment for RA
- Table 17: Pipeline Molecules for RA
- Table 18: Others Pipeline Drug for JAK Inhibitors
- Table 19: AbbVie, Inc.: Financial Performance, 2016-2018
- Table 20: AbbVie Inc.: Product Portfolio
- Table 21: AbbVie Inc.: Pipeline Molecules
- Table 22: AbbVie Inc.: Recent Acquisitions
- Table 23: Classification of SMA
- Table 24: Milestones in Discovery of SMA
- Table 25: Pipeline Molecules, SMA
- Table 26: Novartis AG: Financial Performance, 2016-2018
- Table 27: Novartis AG: Product Portfolio, Oncology
- Table 28: Novartis AG: Product Portfolio, Ophthalmology
- Table 29: Novartis AG: Product Portfolio, Immunology Hepatology and Dermatology
- Table 30: Novartis AG: Product Portfolio, Neuroscience
- Table 31: Novartis AG: Product Portfolio, Respiratory
- Table 32: Novartis AG: Product Portfolio, Pipeline Molecules
- Table 33: Novartis AG: Recent Acquisitions
- Table 34: Therapeutic Trials of Brolicizumab on Safety and Efficacy

- Table 35: Projected Number of People with AMD, by Region, Through 2024
- Table 36: AREDS Classification of AMD
- Table 37: Pipeline Molecules for AMD
- Table 38: Market Size of Lucentis and Eylea, Through 2022
- Table 39: Incident and Prevalent Cases of MS, by Country, 2016
- Table 40: Incident and Prevalent Cases of MS, by Region, 2016
- Table 41: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
- Table 42: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
- Table 43: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
- Table 44: Pipeline Molecules for Multiple Sclerosis Showing Promising Results
- Table 45: Development Milestones of Risankizumab
- Table 46: Currently Available Treatment for Psoriasis, Biologics
- Table 47: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase III
- Table 48: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase II
- Table 49: Global Psoriasis Market, by Region/Country, Through 2022
- Table 50: Pipeline Molecules: Beta Thalassemia
- Table 51: Bluebird Bio Inc.: Financial Performance, 2016-2018
- Table 52: Bluebird Bio Inc.: Pipeline Molecules as of 2019
- Table 53: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
- Table 54: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
- Table 55: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
- Table 56: Pipeline Molecules of Multiple Sclerosis Showing Promising Results
- Table 57: Development Milestones of Ozanimod as of 2019
- Table 58: Celgene Corp.: Revenue Details, 2016-2018
- Table 59: Celgene Corp.: Marketed Products
- Table 60: Celgene Corp.: Company Agreements
- Table 61: Common Symptoms of Peanut Allergy
- Table 62: Common Symptoms of Rheumatoid Arthritis
- Table 63: Unmet Needs of Rheumatoid Arthritis
- Table 64: Current Treatment for Rheumatoid Arthritis
- Table 65: Pipeline Molecules for Rheumatoid Arthritis
- Table 66: Gilead Sciences Inc.: Net Revenue, 2016-2018
- Table 67: Gilead Science Inc.: Marketed Products

Table 68: Gilead Science Inc.: Pipeline Molecules

Table 69: Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

Figure 1: Percentage Distribution of R&D Spending for Clinical Development of Novel Drugs, by Therapeutic Category, 2019

Figure 2: Market Share Analysis of Major Players in the Global Pharmaceutical Industry, 2018

Figure 3: Soliris: Net Product Revenues, 2014-2018

Figure 4: Spinraza: Market Size, 2016-2018

Figure 5: Novartis AG: Spending on Research and Development, by Division, 2017 and 2018

Figure 6: Brolucizumab: Mechanism of Action

Figure 7: Top Eight Food Items Triggering Allergy and Number of Children Affected, 2018

Figure 8: Percentage Distribution of Drug Launches, by Therapeutic Category, 2019

I would like to order

Product name: Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Product link: <https://marketpublishers.com/r/S35EFA975E18EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S35EFA975E18EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

